

Sana M Al-Khatib

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4100677/sana-m-al-khatib-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

5,923
citations

36
h-index

73
g-index

199
ext. papers

7,505
ext. citations

8.9
avg, IF

5.41
L-index

#	Paper	IF	Citations
172	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>American Heart Journal</i> , 2010 , 159, 331-9	4.9	345
171	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2018 , 138, e272-e391	16.7	307
170	Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 1525-32	27.4	278
169	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i> , 2018 , 15, e100-e152	6.7	264
168	Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1883-10	15.1	256
167	Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 1517-24	27.4	191
166	Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1082-7	15.1	189
165	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2018 , 138, e210-e271	16.7	173
164	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1749-58	40	150
163	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Heart Rhythm</i> , 2016 , 13, e50-86	6.7	142
162	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2016 , 133, e506-74	16.7	142
161	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014 , 35, 1448-56	9.5	128
160	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013 , 34, 2464-71	9.5	127
159	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014 , 124, 3692-8	2.2	124
158	Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. <i>Circulation</i> , 2014 , 130, 1037-43	16.7	118
157	2019 HRS/EHRA/APHRS/LAHR expert consensus statement on catheter ablation of ventricular arrhythmias. <i>Europace</i> , 2019 , 21, 1143-1144	3.9	114
156	Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. <i>Annals of Internal Medicine</i> , 2014 , 160, 760-73	8	113

155	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1063-1074	15.1	99
154	Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?. <i>Circulation</i> , 2012 , 125, 1094-101	16.7	98
153	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2171-2187	7	96
152	Rates of cardiopulmonary resuscitation training in the United States. <i>JAMA Internal Medicine</i> , 2014 , 174, 194-201	11.5	89
151	Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2010 , 21, 545-50	2.7	83
150	Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008 , 1, 240-9	6.4	82
149	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Europace</i> , 2016 , 18, 159-83	3.9	80
148	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. <i>Heart Rhythm</i> , 2020 , 17, e2-e154	6.7	80
147	Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 179-86	5.8	71
146	Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1541-50	15.1	67
145	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. <i>Heart Rhythm</i> , 2018 , 15, 651-657	6.7	64
144	Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. <i>JACC: Heart Failure</i> , 2014 , 2, 623-9	7.9	56
143	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. <i>Circulation</i> , 2016 , 134, 517-26	16.7	55
142	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. <i>JAMA Cardiology</i> , 2017 , 2, 685-688	16.2	54
141	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019 , 139, 2292-2300	16.7	47
140	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017 , 40, 1763-1770	14.6	46
139	Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 151-7	2.7	46
138	Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 829-35	4.3	43

137	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2433-40	27.4	38
136	Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. <i>JAMA Cardiology</i> , 2016 , 1, 37-45	16.2	36
135	Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. <i>American Heart Journal</i> , 2015 , 169, 39-44.e2	4.9	35
134	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019 , 208, 123-131	4.9	35
133	Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. <i>American Heart Journal</i> , 2009 , 158, 792-8	4.9	34
132	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	33
131	2019 HRS/EHRA/APHRS/LAHRs expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. <i>Heart Rhythm</i> , 2020 , 17, e155-e205	6.7	33
130	Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. <i>Circulation</i> , 2017 , 136, 1387-1395	16.7	32
129	Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014 , 7, 793-9	6.4	31
128	Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013 , 6, 108-16	6.4	31
127	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 3268-75	9.5	30
126	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016 , 202, 589-94	3.2	29
125	Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 788-96	15.1	28
124	Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: A Report From the National Cardiovascular Data Registry. <i>Circulation</i> , 2016 , 134, 1617-1628	16.7	27
123	Medicine. Placebo-controls in short-term clinical trials of hypertension. <i>Science</i> , 2001 , 292, 2013-5	33.3	27
122	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Journal of Arrhythmia</i> , 2016 , 32, 1-28	1.5	27
121	Primary prevention implantable cardioverter-defibrillators and survival in older women. <i>JACC: Heart Failure</i> , 2015 , 3, 159-67	7.9	26
120	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. <i>Circulation: Heart Failure</i> , 2016 , 9, e002630	7.6	25

119	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. <i>American Heart Journal</i> , 2017 , 191, 21-29	4.9	24
118	Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2209-15	27.4	24
117	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. <i>American Heart Journal</i> , 2017 , 189, 48-58	4.9	23
116	Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 256-64	15.1	23
115	Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation: A Meta-Analysis. <i>JACC: Clinical Electrophysiology</i> , 2018 , 4, 112-120	4.6	22
114	Defibrillators: Selecting the Right Device for the Right Patient. <i>Circulation</i> , 2016 , 134, 1390-1404	16.7	22
113	Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , 2021 , 143, 372-388	16.7	22
112	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018 , 20, 525-532	12.3	21
111	HRS White Paper on interoperability of data from cardiac implantable electronic devices (CIEDs). <i>Heart Rhythm</i> , 2019 , 16, e107-e127	6.7	20
110	Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury "downstream of downstream". <i>European Heart Journal: Acute Cardiovascular Science</i> , 2017 , 4, 516	4.3	20
109	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , 2020 , 141, 1915-1926	16.7	20
108	Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management. <i>American Heart Journal</i> , 2020 , 220, 29-40	4.9	20
107	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2618-2629	15.1	19
106	The Food and Drug Administration and pragmatic clinical trials of marketed medical products. <i>Clinical Trials</i> , 2015 , 12, 511-9	2.2	19
105	Antiarrhythmic drug use in patients. <i>American Journal of Cardiology</i> , 2015 , 115, 316-22	3	18
104	Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , 2020 , 141, 482-492	16.7	17
103	Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. <i>Journal of Cardiac Failure</i> , 2014 , 20, 23-30	3.3	17
102	The subcutaneous implantable cardioverter-defibrillator in review. <i>American Heart Journal</i> , 2019 , 217, 131-139	4.9	16

101	Dofetilide dose reductions and discontinuations in women compared with men. <i>Heart Rhythm</i> , 2018 , 15, 478-484	6.7	16
100	Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank. <i>American Heart Journal</i> , 2010 , 159, 17-24	4.9	16
99	Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. <i>Heart Rhythm</i> , 2016 , 13, 1748-54	6.7	16
98	Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. <i>Europace</i> , 2018 , 20, 1621-1629	3.9	15
97	Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016 , 9,	6.4	15
96	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. <i>Annals of Internal Medicine</i> , 2018 , 169, 774-787	8	15
95	Real-world observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020 , 22, 831-832	3.9	14
94	Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 265-274	15.1	13
93	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 525-534	16.2	13
92	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary. <i>Europace</i> , 2020 , 22, 450-495	3.9	13
91	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016 , 1, 73-9	16.2	13
90	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. <i>International Journal of Cardiology</i> , 2014 , 177, 990-4	3.2	13
89	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e017024	6	13
88	Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016 , 45, 111-7	2.4	12
87	The Association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest. <i>American Heart Journal</i> , 2018 , 204, 156-162	4.9	11
86	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. <i>American Heart Journal</i> , 2013 , 165, 862-8	4.9	11
85	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation</i> , 2017 , 135, 38-47	16.7	11
84	Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE. <i>Circulation: Heart Failure</i> , 2014 , 7, 926-34	7.6	11

83	Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium "Incubator" Think Tank. <i>American Heart Journal</i> , 2010 , 160, 619-26	4.9	11
82	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). <i>Circulation</i> , 2017 , 135, 1136-1144	16.7	10
81	Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015 , 8, 145-51	6.4	10
80	Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. <i>Cardiovascular Digital Health Journal</i> , 2020 , 1, 21-29	2	10
79	One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. <i>European Journal of Heart Failure</i> , 2020 , 22, 859-867	12.3	10
78	Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry® Implantable Cardioverter-Defibrillator Registry. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	10
77	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016 , 171, 25-32	4.9	10
76	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10
75	FDA-Catalyst-Using FDA® Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. <i>Clinical Trials</i> , 2019 , 16, 90-97	2.2	10
74	Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. <i>Heart Rhythm</i> , 2020 , 17, 447-454	6.7	10
73	Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. <i>Journal of General Internal Medicine</i> , 2015 , 30, 1812-20	4	9
72	Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. <i>JACC: Clinical Electrophysiology</i> , 2017 , 3, 20-28	4.6	9
71	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , 2015 , 4, e002061	6	9
70	Changes in the digital health landscape in cardiac electrophysiology: A pre-and peri-pandemic COVID-19 era survey.. <i>Cardiovascular Digital Health Journal</i> , 2021 , 2, 55-62	2	9
69	Temporal Trends in and Factors Associated With Use of Single- Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads: Data From the NCDR ICD Registry. <i>JACC: Clinical Electrophysiology</i> , 2017 , 3, 612-619	4.6	8
68	Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. <i>American Heart Journal</i> , 2018 , 198, 123-128	4.9	8
67	Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2013 , 24, 664-71	2.7	8
66	A case of severe ischemia-induced QT prolongation. <i>Clinical Cardiology</i> , 2001 , 24, 750	3.3	8

65	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
64	Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. <i>European Journal of Cardiovascular Nursing</i> , 2019 , 18, 280-288	3.3	8
63	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). <i>American Journal of Cardiology</i> , 2019 , 124, 1406-1412	3	7
62	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2020 , 223, 48-58	4.9	7
61	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAP-AF risk scoring systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019 , 42, 1440-1447	1.6	7
60	Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. <i>American Journal of Cardiology</i> , 2014 , 114, 716-22	3	7
59	Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 292-300	5.8	7
58	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. <i>JAMA Cardiology</i> , 2021 , 6, 1275-1284	16.2	7
57	Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review. <i>American Heart Journal</i> , 2020 , 229, 52-60	4.9	6
56	Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). <i>American Heart Journal</i> , 2020 , 229, 110-117	4.9	6
55	Stroke prevention in atrial fibrillation: Closing the gap. <i>American Heart Journal</i> , 2019 , 210, 29-38	4.9	6
54	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , 2017 , 119, 886-892	3	5
53	Stellate Ganglion Blockade: an Intervention for the Management of Ventricular Arrhythmias. <i>Current Hypertension Reports</i> , 2020 , 22, 100	4.7	5
52	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 713-720	5.1	5
51	Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. <i>Heart Rhythm</i> , 2015 , 12, 1558-64	6.7	4
50	The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. <i>American Heart Journal</i> , 2018 , 201, 17-24	4.9	4
49	When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?. <i>Cardiac Electrophysiology Clinics</i> , 2018 , 10, 137-144	1.4	4
48	Quality improvement in heart rhythm care: the path forward. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013 , 36, 145-9	2.4	4

47	Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. <i>Clinical Cardiology</i> , 2020 , 43, 187-195	3.3	4
46	Treatment of Older Patients with Atrial Fibrillation by Morbidity Burden. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 ,	4.6	4
45	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020 , 59, 81-133	2.4	3
44	How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?. <i>American Heart Journal</i> , 2018 , 196, 163-169	4.9	3
43	Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 670-9	5.8	3
42	Sex Differences in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	3
41	Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2018 , 11, e005356	7.6	3
40	Catheter ablation of atrial fibrillation in patients with diabetes mellitus. <i>Heart Rhythm O2</i> , 2020 , 1, 180-188	16.8	2
39	2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020 , 59, 145-298	2.4	2
38	Fourth Annual Go Red for Women Issue. <i>Circulation</i> , 2020 , 141, 499-500	16.7	2
37	Acute Treatment of Patients With Supraventricular Tachycardia. <i>JAMA Cardiology</i> , 2016 , 1, 483-5	16.2	2
36	Promise of factor Xa inhibition in atrial fibrillation. <i>Current Cardiology Reports</i> , 2012 , 14, 70-8	4.2	2
35	Applying patient-reported outcome methodology to capture patient-reported health data: Report from an NIH Collaboratory roundtable. <i>Healthcare</i> , 2020 , 8, 100442	1.8	2
34	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. <i>Circulation</i> , 2018 , 138, 2787-2797	16.7	2
33	Knowledge and Insights Vested in Us by the VEST. <i>Circulation</i> , 2018 , 138, 2735-2737	16.7	2
32	Arrhythmias in Female Patients: Incidence, Presentation and Management.. <i>Circulation Research</i> , 2022 , 130, 474-495	15.7	2
31	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". <i>Circulation</i> , 2017 , 135, e22-e23	16.7	1
30	Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. <i>American Journal of Cardiology</i> , 2017 , 119, 1401-1406	14.06	1

29	ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 907-910	7.9	1
28	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 643-651	16.2	1
27	Sex differences in left ventricular electrical dyssynchrony and outcomes with cardiac resynchronization therapy. <i>Heart Rhythm</i> 2020 , 1, 243-249	1.5	1
26	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009614	6.4	1
25	Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e008991	6.4	1
24	Response by Friedman and Al-Khatib to Letter Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry". <i>Circulation</i> , 2018 , 138, 2972-2973	16.7	1
23	Anticoagulation after Ablation for Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2021 , 385, 466-468	9.2	1
22	HRS White Paper on Clinical Utilization of Digital Health Technology.. <i>Cardiovascular Digital Health Journal</i> , 2021 , 2, 196-211	2	1
21	Centers for Medicare and Medicaid Services Decision to Reconsider Coverage Indications for ICDs: Where to Now?. <i>Circulation</i> , 2018 , 137, 317-319	16.7	0
20	Response to letter regarding article, "Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry". <i>Circulation</i> , 2015 , 131, e518	16.7	0
19	Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1622-1630	6.9	0
18	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients \geq 5 Years of Age With a Low Ejection Fraction After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2021 , 138, 26-32	3	0
17	Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT). <i>Resuscitation</i> , 2021 , 168, 75-83	4	0
16	Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022 , 101161	6.4	0
15	Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis. <i>Journal of Interventional Cardiology</i> , 2022 , 2022, 1-10	1.8	0
14	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. <i>JAMA Network Open</i> , 2022 , 5, e2214321	10.4	0
13	Improved patient selection for implantable defibrillators. <i>Lancet, The</i> , 2019 , 394, 1302-1304	40	0
12	Atrial fibrillation and kidney disease: stuck outside the CABANA. <i>Kidney International</i> , 2019 , 96, 1054-1059	5.9	0

11	Authors Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1137-1138	12.7
10	Management of pace-terminated ventricular arrhythmias. <i>Cardiac Electrophysiology Clinics</i> , 2015 , 7, 497-513	5.3
9	Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. <i>American Heart Journal</i> , 2018 , 196, 170-177	4.9
8	Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease?. <i>Current Cardiovascular Risk Reports</i> , 2017 , 11, 1	0.9
7	Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy-Reply. <i>JAMA Cardiology</i> , 2017 , 2, 1283-1284	16.2
6	Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients. <i>Evidence-Based Medicine</i> , 2015 , 20, 217	
5	New directions in clinical outcomes assessment : VIth International Symposium on Interventional Electrophysiology in the Management of Cardiac Arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011 , 32, 221-6	2.4
4	Regulation Without Representation: Cardiac Device Patient Knowledge and Attitudes About the FDA Regulatory Process. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008561	6.4
3	Emerging topics in electrophysiology. <i>Progress in Cardiovascular Diseases</i> , 2021 , 66, 1	8.5
2	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. <i>Progress in Cardiovascular Diseases</i> , 2021 , 66, 53-60	8.5
1	Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. <i>American Heart Journal</i> , 2021 , 233, 151-152	4.9